Now that official COVID emergency declarations have ended, how should people evaluate their risk of SARS-CoV-2? That's the subject of our frequently asked questions offering.
Once U.S. stockpiles of COVID-19 vaccine run out, Moderna says it might charge as much as $130 per dose, but give people who lack health insurance a break. Critics say that's not enough help.
Insurers, employers, taxpayers and other consumers will all be affected as drugmakers move these products to the commercial market in May. How much you'll pay depends on your health insurance.
The new approach would simplify vaccination guidance so that, every fall, people would get a new shot, updated to try to match whatever variant is dominant.
The decision aims to better protect the littlest kids amid an uptick in COVID-19 cases around the country. The Centers for Disease Control and Prevention is expected to sign off soon.
Two reasons for the renewed COVID-19 vaccine campaign include updated booster shots and the approach of fall and winter.
The inventors of Corbevax said it was cheap, easy to make, effective and safe. They hoped it could bring vaccine equity to countries that can't access costlier shots. Has it lived up to its promise?
A coalition of religious groups, conservative think tanks, and Republican attorneys general have chipped away at local and state authority, altering how the nation can respond during health crises.
The Food and Drug Administration will have to decide the exact recipe, but a combination shot is expected that adds protection against a version of the omicron variant to the original vaccine.
COVID vaccines for kids under age 5 were approved last week in a major development to tackle the pandemic. Health experts are telling parents to contact their pediatricians for a shot. But for many, that’s not an option.
CDC advisers are recommending the use of two separate COVID-19 vaccines for the youngest children made by Moderna and Pfizer-BioNTech, paving the way for vaccine rollout as early as next week.
Advisers to the Food and Drug Administration overwhelmingly voted to recommend that it authorize Novavax's two-dose vaccine against COVID-19.
The Food and Drug Administration expanded authorization of Pfizer-BioNTech's COVID vaccine to enable kids ages 5 to 11 who were vaccinated at least five months ago to get a third shot.
During the pandemic scientists launched a vaccine in record-breaking time. Their successful use of mRNA technology could lead to progress in the decades-long effort for an HIV inoculation.